A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492
Phase 1
72
about 2.1 years
18–70
5 sites in AL, CA, IA
What this study is about
Researchers are testing the safety, tolerability, how your body processes (pharmacokinetics), and how the drug affects your body (pharmacodynamics) of a medication called AZD5492. The trial will last for about 782 days and involve adults with conditions like lupus, inflammatory myopathies, or rheumatoid arthritis.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD5492
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety evaluation of AZD5492: Number of SAEs leading to death, Safety evaluation of AZD5492: Number of participants with related treatment-emergent adverse events., Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events by grade., Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events., Tolerability evaluation of AZD5492: Number of participants with abnormal ECG., Tolerability evaluation of AZD5492: Number of participants with treatment-emergent clinical laboratory abnormalities., Tolerability evaluation of AZD5492: Number of participants with treatment-emergent vital signs abnormalities.
Secondary: Serum Pharmacokinetics (PK) parameters of AZD5492 (AUC), Serum Pharmacokinetics (PK) parameters of AZD5492 (AUClast), Serum Pharmacokinetics (PK) parameters of AZD5492 (Cmax), Serum Pharmacokinetics (PK) parameters of AZD5492 (t1/2λz)
Immune